FDA Approves REMIFENTANIL HYDROCHLORIDE — Fresenius Kabi USA, LLC

Fresenius Kabi USA announced the spread of the 50 mg/RBC units FDA approval for remifentanil hydrochloride injections, removing a regulatory hurdle that directly supports manufacturers like Morphotek and AstraZeneca in sustaining the drug’s critical role in intensive care settings. This clears the path for Fresenius to expand distribution channels within a high-growth, niche market dominated by competitors focusing on traditionally difficult supply chains.